Jisoo A. Kwon
Research Interests
Jisoo A. Kwon has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Richard T. Gray
8 shared publicationsJennifer Galouzis
Corrective Services NSW, Sydney, NSW, Australia
5 shared publications- Andrew R. Lloyd
The Kirby Institute, University of New South Wales, Sydney, Australia
4 shared publications Gregory J. Dore
University of New South Wales (UNSW) - Kirby Institute
4 shared publicationsJames Blogg
Justice Health Forensic Mental Health Network NSW, Sydney, NSW, Australia
4 shared publications- Jason Grebely
The Kirby Institute University of New South Wales Sydney New South Wales Australia
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Impact And Cost-Effectiveness Of Scaling Up A National Point-Of-Care Hepatitis C Testing And Treatment Program In Australia: A Mathematical Modelling Study
Background: Point-of-care hepatitis C virus (HCV) antibody and RNA testing can simplify diagnosis and improve treatment initiation compared to the standard-of-care HCV diagnostic algorithm, but its population-level health and economic effects when implemented at scale remain uncertain. The Australian Hepatitis C Point-of-Care Testing Program (National Program) is a real-world national program implementing across community and prison settings. We evaluated the epidemiological impact and cost-effectiveness of its current and future implementation. Methods: We used a dynamic deterministic model of HCV transmission and testing, with parameters informed by empirical implementation, epidemiological, and cost data from the National Program. Current implementation and future sustainment and scale-up scenarios was compared with a no-program counterfactual using standard-of-care HCV diagnostics across community and prison settings. Cost-effectiveness was assessed from the healthcare providers’ perspective over 2022-2041 to capture long-term costs and quality-adjusted life-years (QALYs) beyond 2022-2030 implementation period. Costs and QALYs were discounted at 5% per annum. Findings: Under sustained implementation to 2030, HCV RNA prevalence was projected to decline from 9·5% in 2021 to 2·4% in 2030, versus 3·3% without the Program. Compared with no program, sustained implementation was projected to avert 4,350 infections (13·7%) and facilitate 1,242 treatments (2·3%) over 2022-2030. Over 2022-2041, A$20·5 million in incremental diagnostic costs were offset by reductions in HCV treatment (A$19·9 million) and disease management (A$10·8 million), generating net savings of A$10·2 million and A$1·34 in return per A$1 invested. All scenarios remained cost-effective across sensitivity analyses; while sustained implementation scenario was no longer dominant when treatment price fell to 10% of the PBS-listed price. Interpretation: Sustained national point-of-care HCV testing across community and prison settings was projected to reduce HCV burden and generate long-term health-care savings, mainly through infections averted by treatment as prevention. These findings demonstrate that investment in targeted point-of-care testing infrastructure can deliver health and economic benefits.
- 3 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact And Cost-Effectiveness Of Scaling Up A National Point-Of-Care Hepatitis C Testing And Treatment Program In Australia: A Mathematical Modelling Study
Background: Point-of-care hepatitis C virus (HCV) antibody and RNA testing can simplify diagnosis and improve treatment initiation compared to the standard-of-care HCV diagnostic algorithm, but its population-level health and economic effects when implemented at scale remain uncertain. The Australian Hepatitis C Point-of-Care Testing Program (National Program) is a real-world national program implementing across community and prison settings. We evaluated the epidemiological impact and cost-effectiveness of its current and future implementation. Methods: We used a dynamic deterministic model of HCV transmission and testing, with parameters informed by empirical implementation, epidemiological, and cost data from the National Program. Current implementation and future sustainment and scale-up scenarios was compared with a no-program counterfactual using standard-of-care HCV diagnostics across community and prison settings. Cost-effectiveness was assessed from the healthcare providers’ perspective over 2022-2041 to capture long-term costs and quality-adjusted life-years (QALYs) beyond 2022-2030 implementation period. Costs and QALYs were discounted at 5% per annum. Findings: Under sustained implementation to 2030, HCV RNA prevalence was projected to decline from 9·5% in 2021 to 2·4% in 2030, versus 3·3% without the Program. Compared with no program, sustained implementation was projected to avert 4,350 infections (13·7%) and facilitate 1,242 treatments (2·3%) over 2022-2030. Over 2022-2041, A$20·5 million in incremental diagnostic costs were offset by reductions in HCV treatment (A$19·9 million) and disease management (A$10·8 million), generating net savings of A$10·2 million and A$1·34 in return per A$1 invested. All scenarios remained cost-effective across sensitivity analyses; while sustained implementation scenario was no longer dominant when treatment price fell to 10% of the PBS-listed price. Interpretation: Sustained national point-of-care HCV testing across community and prison settings was projected to reduce HCV burden and generate long-term health-care savings, mainly through infections averted by treatment as prevention. These findings demonstrate that investment in targeted point-of-care testing infrastructure can deliver health and economic benefits.
- Open Access
Evaluating the impact of COVID-19 on the HIV epidemic among men who have sex with men in Australia: A modelling study
Introduction The initial phase of the coronavirus disease 2019 (COVID-19) pandemic caused significant interruptions to human immunodeficiency virus (HIV) prevention and healthcare services. In Australia, these interruptions coincided with a large reduction in HIV diagnoses but it is unknown if this reflects a reduction in incidence or barriers to testing. We aimed to understand the changes in HIV transmission among men who have sex with men in Australia and the impact of disruptions to HIV prevention, testing and treatment services due to the COVID-19 pandemic and the public health response by incorporating time-sensitive factors in real-world situations. Methods We developed a mathematical model to estimate monthly HIV incidence between January 2020 and August 2022. We obtained aggregated monthly data for sexual partners, condom use, HIV testing, pre-exposure prophylaxis (PrEP) use, and migration. Three scenarios were simulated: 1) a COVID scenario with all changes in place; 2) a no COVID-19 scenario where input parameters remained at pre-COVID-19 values, and 3) a no COVID-19 scenario with continued PrEP scale-up. Results In the absence of the COVID-19 pandemic, the estimated number of cumulative infections from January 2020 to August 2022 would have been 1,266 [95% Percentile Interval (PI): 1,100–1,466] compared to 915 [95% PI: 729–1,181] for the COVID-19 scenario (a 27.7% reduction). The largest reduction in infections (44.3%) occurred in 2020 with 273 (95% PI: 221– 344) infections versus 490 (95% PI: 435–552) in the no-COVID scenario. There was a rebound with 387 infections (95% PI: 307–502) in 2021, followed by a reduction to a stable level by August 2022. Our model identified reductions in sexual partners as the leading factor contributing to the change in HIV infections and diagnoses (−24.8% and −10.5%, respectively). Conclusions A substantial reduction in new HIV infections and diagnoses in Australia occurred during the early stages of the COVID-19 pandemic, which was largely due to reduced HIV transmission. A rebound in infections as sexual partnerships increased between 2021-2022, highlights the imperative to maintain vigorous response efforts and take advantage of the gains made to virtually eliminate HIV transmission in Australia.
Open AccessEvaluating the impact of COVID-19 on the HIV epidemic among men who have sex with men in Australia: A modelling study
Introduction The initial phase of the coronavirus disease 2019 (COVID-19) pandemic caused significant interruptions to human immunodeficiency virus (HIV) prevention and healthcare services. In Australia, these interruptions coincided with a large reduction in HIV diagnoses but it is unknown if this reflects a reduction in incidence or barriers to testing. We aimed to understand the changes in HIV transmission among men who have sex with men in Australia and the impact of disruptions to HIV prevention, testing and treatment services due to the COVID-19 pandemic and the public health response by incorporating time-sensitive factors in real-world situations. Methods We developed a mathematical model to estimate monthly HIV incidence between January 2020 and August 2022. We obtained aggregated monthly data for sexual partners, condom use, HIV testing, pre-exposure prophylaxis (PrEP) use, and migration. Three scenarios were simulated: 1) a COVID scenario with all changes in place; 2) a no COVID-19 scenario where input parameters remained at pre-COVID-19 values, and 3) a no COVID-19 scenario with continued PrEP scale-up. Results In the absence of the COVID-19 pandemic, the estimated number of cumulative infections from January 2020 to August 2022 would have been 1,266 [95% Percentile Interval (PI): 1,100–1,466] compared to 915 [95% PI: 729–1,181] for the COVID-19 scenario (a 27.7% reduction). The largest reduction in infections (44.3%) occurred in 2020 with 273 (95% PI: 221– 344) infections versus 490 (95% PI: 435–552) in the no-COVID scenario. There was a rebound with 387 infections (95% PI: 307–502) in 2021, followed by a reduction to a stable level by August 2022. Our model identified reductions in sexual partners as the leading factor contributing to the change in HIV infections and diagnoses (−24.8% and −10.5%, respectively). Conclusions A substantial reduction in new HIV infections and diagnoses in Australia occurred during the early stages of the COVID-19 pandemic, which was largely due to reduced HIV transmission. A rebound in infections as sexual partnerships increased between 2021-2022, highlights the imperative to maintain vigorous response efforts and take advantage of the gains made to virtually eliminate HIV transmission in Australia.
- Open Access
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1478843
Corrigendum: Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries
Since the start of the coronavirus disease (COVID-19) pandemic in early 2020, correctional facilities around the world have experienced significant outbreaks of severe-acute-respiratorysyndrome-related coronavirus (SARS-CoV-2) (1)(2)(3)(4)(5). Such facilities (including gaols/jails, prisons, and other custodial settings), termed here "prisons", are vulnerable to outbreaks of SARS-CoV-2 and other highly transmissible respiratory infections due to their congregate nature with unavoidable close contact between people. People in prison are particularly vulnerable to severe COVID-19 given the higher prevalence of co-morbidities and poorer social determinants of health compared to the general population (2,6,7). Prisons' enclosed environments mean that SARS-CoV-2 can easily spread between people in prison, correctional and healthcare staff (for an Australian prison setting and this terminology will be used throughout the manuscript)/correctional employees (in a Canadian prison setting), and visitors.The transfer of people in prison between correctional facilities and into the community can also fuel outbreaks in other facilities and into surrounding communities (8). Significant outbreaks of COVID-19 occurred in high-income country prison settings. For example, there was a reported 50% prevalence of COVID-19 among inmates in the Federal Training Centre of Correctional Service of Canada (9) and in a residential treatment unit at the Cook County Jail, Chicago, Illinois, USA (10)during 2020. In another prison setting in the USA, the attack rate was estimated at 82% in one dormitory during April-May 2020 (11).Prisons are therefore high-priority settings for coordinated public health responses to the COVID-19 pandemic and future outbreaks of other respiratory infections (3,(12)(13)(14)(15). However, the response to COVID-19 in prisons has been hampered due to limited access and use of personal protective equipment (PPE) in resource-limited settings, poorer access and delay the vaccination and vaccine hesitancy, security and logistical constraints, frequent movement of people between correctional settings, and the continuous entry and exit of people into the prison (16)(17)(18)(19)(20). Correctional settings, therefore, require system-level and evidence-based responses (21,22).There have been several modelling studies evaluating the potential impact of prison-specific interventions to mitigate COVID-19 outbreaks in correctional settings. It was estimated that a large COVID-19 outbreak would be expected in prisons without both non-pharmaceutical interventions (NPIs) such as the use of PPE for people in prison and staff, decarceration of people in prison, quarantine at reception, isolation of people who are infected with COVID-19, and vaccination (23)(24)(25)(26)(27), particularly with delta and omicron variants (28)(29)(30), resulting in significant mortality (31). These models, however, did not consider the heterogeneous transmission network inside prisons, the characteristics of the population (among whom there is an increased risk of severe disease), and, for the most part, failed to use real-world data for calibration. These previous studies also neglected to focus on the combination of public health interventions that could potentially mitigate COVID-19 outbreaks. To our knowledge, this is the first study which has sought to model a combination of intervention strategies using models validated with 'real-world' data. In this study, we aimed to develop a COVID-19 model for two high-income prison settings in Australia and Canada and validate the model outputs against outbreak data from these two settings, and evaluate the potential impact of various intervention scenarios in averting cases and morbidity.We previously developed a COVID-19 Incarceration model by expanding on an existing spreadsheet model originally developed by Recidiviz (https://www.recidiviz.org) (32). The model aimed to capture additional complex features within prison environments, to reflect the mixing patterns between people in prison and correctional and healthcare staff, and to model a The Australian prison is a maximum-level quarantine prison with approximately 1,000 adult men (>18 years old). The Canadian prison is the largest provincial prison in Quebec, where it was the epicenter of the SARS-CoV-2 epidemic, with a capacity of 1,400 adult men (>18 years old) (34,35). Both prisons experienced SARS-CoV-2 outbreaks while multiple non pharmaceutical interventions (NPIs) were in place, but prior to a vaccine being available. A more detailed explanation of COVID-19 outbreaks in both prisons and interventions implemented will be explained later.The scenarios and structures of the model were informed by a reference group drawn from both healthcare and correctional organizations. A detailed explanation of the model structure is available elsewhere (36). Here we provide a summary and focus on the intervention scenarios investigated in the two settings. Briefly, the model is compartmental and implemented in Microsoft Excel (Redmond, WA). The model includes compartments representing the number of people in prison and staff who are susceptible, exposed, infectious, have mild illness, severe illness, are hospitalized, and recovered, with the number of deaths and new infections calculated daily (Figure 1). The model incorporates potential virus transmission between people in prison, correctional and healthcare staff, and visitors. It allows the designation of the prevalence of vulnerabilities in the population which could lead to severe COVID-19 disease, varied numbers of close contacts, and the daily intake and release of people in prison. 1). Agespecific infection fatality rates were specified for each age group. As people in prison enter the prison, they are allocated to each age group based on the age distribution of the people currently incarcerated. The model is implemented in a difference equation framework with the...
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1478843
Open AccessCorrigendum: Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries
Since the start of the coronavirus disease (COVID-19) pandemic in early 2020, correctional facilities around the world have experienced significant outbreaks of severe-acute-respiratorysyndrome-related coronavirus (SARS-CoV-2) (1)(2)(3)(4)(5). Such facilities (including gaols/jails, prisons, and other custodial settings), termed here "prisons", are vulnerable to outbreaks of SARS-CoV-2 and other highly transmissible respiratory infections due to their congregate nature with unavoidable close contact between people. People in prison are particularly vulnerable to severe COVID-19 given the higher prevalence of co-morbidities and poorer social determinants of health compared to the general population (2,6,7). Prisons' enclosed environments mean that SARS-CoV-2 can easily spread between people in prison, correctional and healthcare staff (for an Australian prison setting and this terminology will be used throughout the manuscript)/correctional employees (in a Canadian prison setting), and visitors.The transfer of people in prison between correctional facilities and into the community can also fuel outbreaks in other facilities and into surrounding communities (8). Significant outbreaks of COVID-19 occurred in high-income country prison settings. For example, there was a reported 50% prevalence of COVID-19 among inmates in the Federal Training Centre of Correctional Service of Canada (9) and in a residential treatment unit at the Cook County Jail, Chicago, Illinois, USA (10)during 2020. In another prison setting in the USA, the attack rate was estimated at 82% in one dormitory during April-May 2020 (11).Prisons are therefore high-priority settings for coordinated public health responses to the COVID-19 pandemic and future outbreaks of other respiratory infections (3,(12)(13)(14)(15). However, the response to COVID-19 in prisons has been hampered due to limited access and use of personal protective equipment (PPE) in resource-limited settings, poorer access and delay the vaccination and vaccine hesitancy, security and logistical constraints, frequent movement of people between correctional settings, and the continuous entry and exit of people into the prison (16)(17)(18)(19)(20). Correctional settings, therefore, require system-level and evidence-based responses (21,22).There have been several modelling studies evaluating the potential impact of prison-specific interventions to mitigate COVID-19 outbreaks in correctional settings. It was estimated that a large COVID-19 outbreak would be expected in prisons without both non-pharmaceutical interventions (NPIs) such as the use of PPE for people in prison and staff, decarceration of people in prison, quarantine at reception, isolation of people who are infected with COVID-19, and vaccination (23)(24)(25)(26)(27), particularly with delta and omicron variants (28)(29)(30), resulting in significant mortality (31). These models, however, did not consider the heterogeneous transmission network inside prisons, the characteristics of the population (among whom there is an increased risk of severe disease), and, for the most part, failed to use real-world data for calibration. These previous studies also neglected to focus on the combination of public health interventions that could potentially mitigate COVID-19 outbreaks. To our knowledge, this is the first study which has sought to model a combination of intervention strategies using models validated with 'real-world' data. In this study, we aimed to develop a COVID-19 model for two high-income prison settings in Australia and Canada and validate the model outputs against outbreak data from these two settings, and evaluate the potential impact of various intervention scenarios in averting cases and morbidity.We previously developed a COVID-19 Incarceration model by expanding on an existing spreadsheet model originally developed by Recidiviz (https://www.recidiviz.org) (32). The model aimed to capture additional complex features within prison environments, to reflect the mixing patterns between people in prison and correctional and healthcare staff, and to model a The Australian prison is a maximum-level quarantine prison with approximately 1,000 adult men (>18 years old). The Canadian prison is the largest provincial prison in Quebec, where it was the epicenter of the SARS-CoV-2 epidemic, with a capacity of 1,400 adult men (>18 years old) (34,35). Both prisons experienced SARS-CoV-2 outbreaks while multiple non pharmaceutical interventions (NPIs) were in place, but prior to a vaccine being available. A more detailed explanation of COVID-19 outbreaks in both prisons and interventions implemented will be explained later.The scenarios and structures of the model were informed by a reference group drawn from both healthcare and correctional organizations. A detailed explanation of the model structure is available elsewhere (36). Here we provide a summary and focus on the intervention scenarios investigated in the two settings. Briefly, the model is compartmental and implemented in Microsoft Excel (Redmond, WA). The model includes compartments representing the number of people in prison and staff who are susceptible, exposed, infectious, have mild illness, severe illness, are hospitalized, and recovered, with the number of deaths and new infections calculated daily (Figure 1). The model incorporates potential virus transmission between people in prison, correctional and healthcare staff, and visitors. It allows the designation of the prevalence of vulnerabilities in the population which could lead to severe COVID-19 disease, varied numbers of close contacts, and the daily intake and release of people in prison. 1). Agespecific infection fatality rates were specified for each age group. As people in prison enter the prison, they are allocated to each age group based on the age distribution of the people currently incarcerated. The model is implemented in a difference equation framework with the...
- Open Access
- 17 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303062
Controlling COVID-19 outbreaks in the correctional setting: A mathematical modelling study
Correctional centres (termed here ‘prisons’) are at high risk of COVID-19 and have featured major outbreaks worldwide. Inevitable close contacts, frequent inmate movements, and a disproportionate burden of co-morbidities mean these environments need to be prioritised in any public health response to respiratory pathogens such as COVID-19. We developed an individual-based SARS-CoV-2 transmission model for the prison system in New South Wales, Australia ‐ incorporating all 33 correctional centres, 13,458 inmates, 578 healthcare and 6,909 custodial staff. Potential COVID-19 disease outbreaks were assessed under various mitigation strategies, including quarantine on entry, isolation of cases, rapid antigen testing of staff, as well as immunisation.Without control measures, the model projected a peak of 472 new infections daily by day 35 across the prison system, with all inmates infected by day 120. The most effective individual mitigation strategies were high immunisation coverage and prompt lockdown of centres with infected inmates which reduced outbreak size by 62–73%. Other than immunisation, the combination of quarantine of inmates at entry, isolation of proven or suspected cases, and widespread use of personal protective equipment by staff and inmates was the most effective strategy. High immunisation coverage mitigates the spread of COVID-19 within and between correctional settings but is insufficient alone. Maintaining quarantine and isolation, along with high immunisation levels, will allow correctional systems to function with a low risk of outbreaks. These results have informed public health policy for respiratory pathogens in Australian correctional systems.
- 17 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0303062
Open AccessControlling COVID-19 outbreaks in the correctional setting: A mathematical modelling study
Correctional centres (termed here ‘prisons’) are at high risk of COVID-19 and have featured major outbreaks worldwide. Inevitable close contacts, frequent inmate movements, and a disproportionate burden of co-morbidities mean these environments need to be prioritised in any public health response to respiratory pathogens such as COVID-19. We developed an individual-based SARS-CoV-2 transmission model for the prison system in New South Wales, Australia ‐ incorporating all 33 correctional centres, 13,458 inmates, 578 healthcare and 6,909 custodial staff. Potential COVID-19 disease outbreaks were assessed under various mitigation strategies, including quarantine on entry, isolation of cases, rapid antigen testing of staff, as well as immunisation.Without control measures, the model projected a peak of 472 new infections daily by day 35 across the prison system, with all inmates infected by day 120. The most effective individual mitigation strategies were high immunisation coverage and prompt lockdown of centres with infected inmates which reduced outbreak size by 62–73%. Other than immunisation, the combination of quarantine of inmates at entry, isolation of proven or suspected cases, and widespread use of personal protective equipment by staff and inmates was the most effective strategy. High immunisation coverage mitigates the spread of COVID-19 within and between correctional settings but is insufficient alone. Maintaining quarantine and isolation, along with high immunisation levels, will allow correctional systems to function with a low risk of outbreaks. These results have informed public health policy for respiratory pathogens in Australian correctional systems.
- Open Access
- 15 March 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1279572
Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries
Introduction: Correctional facilities are high-priority settings for coordinated public health responses to the COVID-19 pandemic. These facilities are at high risk of disease transmission due to close contacts between people in prison and with the wider community. People in prison are also vulnerable to severe disease given their high burden of co-morbidities.Methods: We developed a mathematical model to evaluate the effect of various public health interventions, including vaccination, on the mitigation of COVID-19 outbreaks, applying it to prisons in Australia and Canada.Results: We found that, in the absence of any intervention, an outbreak would occur and infect almost 100% of people in prison within 20 days of the index case. However, the rapid rollout of vaccines with other non-pharmaceutical interventions would almost eliminate the risk of an outbreak.Discussion: Our study highlights that high vaccination coverage is required for variants with high transmission probability to completely mitigate the outbreak risk in prisons.
- 15 March 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1279572
Open AccessPreparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries
Introduction: Correctional facilities are high-priority settings for coordinated public health responses to the COVID-19 pandemic. These facilities are at high risk of disease transmission due to close contacts between people in prison and with the wider community. People in prison are also vulnerable to severe disease given their high burden of co-morbidities.Methods: We developed a mathematical model to evaluate the effect of various public health interventions, including vaccination, on the mitigation of COVID-19 outbreaks, applying it to prisons in Australia and Canada.Results: We found that, in the absence of any intervention, an outbreak would occur and infect almost 100% of people in prison within 20 days of the index case. However, the rapid rollout of vaccines with other non-pharmaceutical interventions would almost eliminate the risk of an outbreak.Discussion: Our study highlights that high vaccination coverage is required for variants with high transmission probability to completely mitigate the outbreak risk in prisons.
- Open Access
Preparing correctional settings for the next pandemic: a modelling study of COVID-19 outbreaks in two high-income countries
Correctional facilities are high-priority settings for coordinated public health responses to the COVID-19 pandemic. These facilities are at high risk of disease transmission due to close contacts between people in prison and with the wider community. People in prison are also vulnerable to severe disease given their high burden of co-morbidities. We developed a mathematical model to evaluate the effect of various public health interventions, including vaccination, on the mitigation of COVID-19 outbreaks, applying it to prisons in Australia and Canada. We found that, in the absence of any intervention, an outbreak would occur and infect almost 100% of people in prison within 20 days of the index case. However, the rapid rollout of vaccines with other non-pharmaceutical interventions would almost eliminate the risk of an outbreak. Our study highlights that high vaccination coverage is required for variants with high transmission probability to completely mitigate the outbreak risk in prisons. Article Summary Line High vaccination coverage is required to eliminate the risk of an outbreak in prisons
Open AccessPreparing correctional settings for the next pandemic: a modelling study of COVID-19 outbreaks in two high-income countries
Correctional facilities are high-priority settings for coordinated public health responses to the COVID-19 pandemic. These facilities are at high risk of disease transmission due to close contacts between people in prison and with the wider community. People in prison are also vulnerable to severe disease given their high burden of co-morbidities. We developed a mathematical model to evaluate the effect of various public health interventions, including vaccination, on the mitigation of COVID-19 outbreaks, applying it to prisons in Australia and Canada. We found that, in the absence of any intervention, an outbreak would occur and infect almost 100% of people in prison within 20 days of the index case. However, the rapid rollout of vaccines with other non-pharmaceutical interventions would almost eliminate the risk of an outbreak. Our study highlights that high vaccination coverage is required for variants with high transmission probability to completely mitigate the outbreak risk in prisons. Article Summary Line High vaccination coverage is required to eliminate the risk of an outbreak in prisons
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis
Background: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard of care. Methods: Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard of care in needle and syringe programs, drug treatment clinics, and prisons. Point-of-care testing strategies included immediate point-of-care HCV RNA testing and combined point-of-care HCV antibody and reflex RNA testing for HCV antibody positive people (with and without consideration of previous treatment). Sensitivity analyses were performed to investigate the cost per treatment initiation with different testing strategies at different HCV antibody prevalence levels. Findings: The average costs per HCV treatment initiation by point-of-care testing were up to 35% lower (A$890–A$1,406) compared to standard of care (A$1,248–A$1,632) depending on settings. The average costs per treatment initiation by point-of-care testing were A$1,080–A$1,406 for RNA, A$960–A$1,310 for combined antibody/RNA without treatment history consideration, and A$890– A$1,189 for combined antibody/RNA with treatment history consideration. When HCV antibody prevalence was <74%, combined point-of-care HCV antibody and point-of-care RNA testing (with and without consideration of treatment history) were the most cost-effective strategies. Modest increases in treatment uptake by 8%-31% were required for immediate point-of-care HCV RNA testing to achieve equivalent cost per treatment initiation compared to standard of care. Interpretation: Point-of-care testing is more cost-effective than standard of care for populations at risk of HCV. Testing strategies combining point-of-care HCV antibody and RNA testing are likely to be cost-effective in most settings. Funding: National Health and Medical Research Council Declaration of Interest: RTG has received funding for his research from WHO and has provided non-funded project advice to Gilead and ViiV. YS is a co-investigator on investigatorinitiated research grants from AbbVie and Gilead Sciences. ARL has received investigatorinitiated research grants from AbbVie, Gilead Sciences, and Sequiris. GJD is a consultant/advisor and has received research grants from Abbvie, Abbot Diagnostics, Gilead Sciences, Bristol Myers Squibb, Cepheid, GlaxoSmithKline, Merck, Janssen and Roche. JG is a consultant/advisor and has received research grants from AbbVie, Biolytical, Camurus, Cepheid, Gilead Sciences, Hologic, Indivor, and Merck/MSD and has received honoraria from AbbVie, Cepheid, Gilead Sciences, and Merck. No input into this work was provided by any of the above listed organisations or institutions. All other authors have no conflicts of interest to declare.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessOptimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis
Background: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard of care. Methods: Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard of care in needle and syringe programs, drug treatment clinics, and prisons. Point-of-care testing strategies included immediate point-of-care HCV RNA testing and combined point-of-care HCV antibody and reflex RNA testing for HCV antibody positive people (with and without consideration of previous treatment). Sensitivity analyses were performed to investigate the cost per treatment initiation with different testing strategies at different HCV antibody prevalence levels. Findings: The average costs per HCV treatment initiation by point-of-care testing were up to 35% lower (A$890–A$1,406) compared to standard of care (A$1,248–A$1,632) depending on settings. The average costs per treatment initiation by point-of-care testing were A$1,080–A$1,406 for RNA, A$960–A$1,310 for combined antibody/RNA without treatment history consideration, and A$890– A$1,189 for combined antibody/RNA with treatment history consideration. When HCV antibody prevalence was <74%, combined point-of-care HCV antibody and point-of-care RNA testing (with and without consideration of treatment history) were the most cost-effective strategies. Modest increases in treatment uptake by 8%-31% were required for immediate point-of-care HCV RNA testing to achieve equivalent cost per treatment initiation compared to standard of care. Interpretation: Point-of-care testing is more cost-effective than standard of care for populations at risk of HCV. Testing strategies combining point-of-care HCV antibody and RNA testing are likely to be cost-effective in most settings. Funding: National Health and Medical Research Council Declaration of Interest: RTG has received funding for his research from WHO and has provided non-funded project advice to Gilead and ViiV. YS is a co-investigator on investigatorinitiated research grants from AbbVie and Gilead Sciences. ARL has received investigatorinitiated research grants from AbbVie, Gilead Sciences, and Sequiris. GJD is a consultant/advisor and has received research grants from Abbvie, Abbot Diagnostics, Gilead Sciences, Bristol Myers Squibb, Cepheid, GlaxoSmithKline, Merck, Janssen and Roche. JG is a consultant/advisor and has received research grants from AbbVie, Biolytical, Camurus, Cepheid, Gilead Sciences, Hologic, Indivor, and Merck/MSD and has received honoraria from AbbVie, Cepheid, Gilead Sciences, and Merck. No input into this work was provided by any of the above listed organisations or institutions. All other authors have no conflicts of interest to declare.
- Open Access
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257369
Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis-cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030.
- 16 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257369
Open AccessAustralia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis-cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030.
- Open Access
The COVID-19 Incarceration Model: a tool for corrections staff to analyze outbreaks of COVID-19
Correctional facilities are at high risk of COVID-19 outbreaks due to the inevitable close contacts in the environment. Such facilities are a high priority in the public health response to the epidemic. We developed a user-friendly Excel spreadsheet model (building on the previously developed Recidiviz model) to analyze COVID-19 outbreaks in correctional facilities and the potential impact of prevention strategies - the COVID-19 Incarceration Model. The model requires limited inputs and can be used by non-modelers. The impact of a COVID-19 outbreak and mitigation strategies is illustrated for an example prison setting.
Open AccessThe COVID-19 Incarceration Model: a tool for corrections staff to analyze outbreaks of COVID-19
Correctional facilities are at high risk of COVID-19 outbreaks due to the inevitable close contacts in the environment. Such facilities are a high priority in the public health response to the epidemic. We developed a user-friendly Excel spreadsheet model (building on the previously developed Recidiviz model) to analyze COVID-19 outbreaks in correctional facilities and the potential impact of prevention strategies - the COVID-19 Incarceration Model. The model requires limited inputs and can be used by non-modelers. The impact of a COVID-19 outbreak and mitigation strategies is illustrated for an example prison setting.
- Open Access
- 11 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0245896
Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis
In Australian prisons approximately 20% of inmates are chronically infected with hepatitis C virus (HCV), providing an important population for targeted treatment and prevention. A dynamic mathematical model of HCV transmission was used to assess the impact of increasing direct-acting antiviral (DAA) treatment uptake on HCV incidence and prevalence in the prisons in New South Wales, Australia, and to assess the cost-effectiveness of alternate treatment strategies. We developed four separate models reflecting different average prison lengths of stay (LOS) of 2, 6, 24, and 36 months. Each model considered four DAA treatment coverage scenarios of 10% (status-quo), 25%, 50%, and 90% over 2016–2045. For each model and scenario, we estimated the lifetime burden of disease, costs and changes in quality-adjusted life years (QALYs) in prison and in the community during 2016–2075. Costs and QALYs were discounted 3.5% annually and adjusted to 2015 Australian dollars. Compared to treating 10% of infected prisoners, increasing DAA coverage to 25%, 50%, and 90% reduced HCV incidence in prisons by 9–33% (2-months LOS), 26–65% (6-months LOS), 37–70% (24-months LOS), and 35–65% (36-months LOS). DAA treatment was highly cost-effective among all LOS models at conservative willingness-to-pay thresholds. DAA therapy became increasingly cost-effective with increasing coverage. Compared to 10% treatment coverage, the incremental cost per QALY ranged from $497-$569 (2-months LOS), -$280–$323 (6-months LOS), -$432–$426 (24-months LOS), and -$245–$477 (36-months LOS). Treating more than 25% of HCV-infected prisoners with DAA therapy is highly cost-effective. This study shows that treating HCV-infected prisoners is highly cost-effective and should be a government priority for the global HCV elimination effort.
- 11 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0245896
Open AccessHepatitis C treatment strategies in prisons: A cost-effectiveness analysis
In Australian prisons approximately 20% of inmates are chronically infected with hepatitis C virus (HCV), providing an important population for targeted treatment and prevention. A dynamic mathematical model of HCV transmission was used to assess the impact of increasing direct-acting antiviral (DAA) treatment uptake on HCV incidence and prevalence in the prisons in New South Wales, Australia, and to assess the cost-effectiveness of alternate treatment strategies. We developed four separate models reflecting different average prison lengths of stay (LOS) of 2, 6, 24, and 36 months. Each model considered four DAA treatment coverage scenarios of 10% (status-quo), 25%, 50%, and 90% over 2016–2045. For each model and scenario, we estimated the lifetime burden of disease, costs and changes in quality-adjusted life years (QALYs) in prison and in the community during 2016–2075. Costs and QALYs were discounted 3.5% annually and adjusted to 2015 Australian dollars. Compared to treating 10% of infected prisoners, increasing DAA coverage to 25%, 50%, and 90% reduced HCV incidence in prisons by 9–33% (2-months LOS), 26–65% (6-months LOS), 37–70% (24-months LOS), and 35–65% (36-months LOS). DAA treatment was highly cost-effective among all LOS models at conservative willingness-to-pay thresholds. DAA therapy became increasingly cost-effective with increasing coverage. Compared to 10% treatment coverage, the incremental cost per QALY ranged from $497-$569 (2-months LOS), -$280–$323 (6-months LOS), -$432–$426 (24-months LOS), and -$245–$477 (36-months LOS). Treating more than 25% of HCV-infected prisoners with DAA therapy is highly cost-effective. This study shows that treating HCV-infected prisoners is highly cost-effective and should be a government priority for the global HCV elimination effort.